Latest News
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update
Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser, Cybin highlighted key advancements that...
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023
- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) -- For reference, pooled data from 232 industry...
Cybin to Acquire Small Pharma Inc.
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy -- Combined portfolio creates the industry's largest, most advanced, well-protected deuterated DMT program -- Combination creates the largest intellectual property portfolio...
Cybin to Participate at the 26th Annual Milken Institute Global Conference
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today...
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today...
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will...
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder in Psychedelics Discussions
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Doug Drysdale and Chopra Foundation founder Deepak Chopra will be participating together on a panel at the upcoming South by Southwest(R) (SXSW) Conference; the title of the panel is “Open Minds:...
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® and The Chopra Foundation, a not-for-profit organization dedicated to improving health...
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced significant progress updates for its two lead clinical development...
Cybin Announces Streamlined Clinical Alignment
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced a streamlining plan aimed at maximizing the Company’s operating...
Cybin (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report
Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its third quarter performance as well as recent business highlights; the report is for the period ended...
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today reported unaudited financial results for its third quarter ended December 31,...
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® is pleased to announce that it has received approval from an independent ethics...
Cybin (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled from 10 to 11:30 a.m. ET. The Cybin...
Cybin to Host Virtual R&D Day on February 28, 2023
Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced that it will host a virtual R&D Day on Tuesday, February 28, 2023, from...
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced key highlights from the completed feasibility study conducted by its...
Cybin (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004
Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive...
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biotechnology company focused on progressing Psychedelics to Therapeutics ® today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without...
Cybin (NEO: CYBN) (NYSE American: CYBN) Releases Update on Clinical Programs
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status of its two clinical programs aimed at...